WO2011011631A3 - Nucleic acid delivery vehicles - Google Patents

Nucleic acid delivery vehicles Download PDF

Info

Publication number
WO2011011631A3
WO2011011631A3 PCT/US2010/042951 US2010042951W WO2011011631A3 WO 2011011631 A3 WO2011011631 A3 WO 2011011631A3 US 2010042951 W US2010042951 W US 2010042951W WO 2011011631 A3 WO2011011631 A3 WO 2011011631A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid delivery
delivery vehicles
nanoparticle
vitro
Prior art date
Application number
PCT/US2010/042951
Other languages
French (fr)
Other versions
WO2011011631A2 (en
Inventor
Samuel Zalipsky
Li Wang
Zhongli Ding
Bing Luo
Original Assignee
Samuel Zalipsky
Li Wang
Zhongli Ding
Bing Luo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samuel Zalipsky, Li Wang, Zhongli Ding, Bing Luo filed Critical Samuel Zalipsky
Publication of WO2011011631A2 publication Critical patent/WO2011011631A2/en
Publication of WO2011011631A3 publication Critical patent/WO2011011631A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides a stable nanoparticle for nucleic acid delivery to cells and tissues in vitro and in vivo, methods for making and using the nanoparticle for at least therapeutic and diagnostic purposes.
PCT/US2010/042951 2009-07-22 2010-07-22 Nucleic acid delivery vehicles WO2011011631A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22749509P 2009-07-22 2009-07-22
US61/227,495 2009-07-22

Publications (2)

Publication Number Publication Date
WO2011011631A2 WO2011011631A2 (en) 2011-01-27
WO2011011631A3 true WO2011011631A3 (en) 2011-03-17

Family

ID=43499663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/042951 WO2011011631A2 (en) 2009-07-22 2010-07-22 Nucleic acid delivery vehicles

Country Status (1)

Country Link
WO (1) WO2011011631A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012113413A1 (en) * 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
CN104379637A (en) * 2012-02-03 2015-02-25 联邦科学和工业研究组织 Branched polymers
MX369469B (en) 2013-08-21 2019-11-08 Curevac Ag Respiratory syncytial virus (rsv) vaccine.
JP7512207B2 (en) * 2018-05-24 2024-07-08 サーナオミクス インコーポレイテッド Compositions and methods of tunable co-coupled polypeptide nanoparticle delivery systems for nucleic acid therapeutics - Patents.com
CA3109138A1 (en) * 2018-08-14 2020-02-20 Loxegen Holdings Pty Ltd Nanoparticles for transfection
CN109758588B (en) * 2019-03-08 2022-02-22 苏州维益生物科技有限公司 Preparation method and application of nucleic acid spherical nanoparticle medicine
AU2020357078A1 (en) * 2019-10-04 2022-05-26 Sirnaomics, Inc. Tumor-targeting polypeptide nanoparticle delivery system for nucleic acid therapeutics

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040166158A1 (en) * 1997-07-03 2004-08-26 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited. Conjugate of polyethylene glycol and chitosan
US20070054337A1 (en) * 2003-09-19 2007-03-08 Ferning David G Nanoparticle conjugates and method of production thereof
US20070086983A1 (en) * 2003-09-05 2007-04-19 The Texas A&M University System Endothelium-targeting nanoparticle for reversing endothelial dysfunction
US20070141134A1 (en) * 2005-12-16 2007-06-21 Kosak Matthew K Shielded micelles for polynucleotide delivery
US20080020058A1 (en) * 2005-02-14 2008-01-24 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US20080166414A1 (en) * 2004-01-28 2008-07-10 Johns Hopkins University Drugs And Gene Carrier Particles That Rapidly Move Through Mucous Barriers

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040166158A1 (en) * 1997-07-03 2004-08-26 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited. Conjugate of polyethylene glycol and chitosan
US20070086983A1 (en) * 2003-09-05 2007-04-19 The Texas A&M University System Endothelium-targeting nanoparticle for reversing endothelial dysfunction
US20070054337A1 (en) * 2003-09-19 2007-03-08 Ferning David G Nanoparticle conjugates and method of production thereof
US20080166414A1 (en) * 2004-01-28 2008-07-10 Johns Hopkins University Drugs And Gene Carrier Particles That Rapidly Move Through Mucous Barriers
US20080020058A1 (en) * 2005-02-14 2008-01-24 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US20070141134A1 (en) * 2005-12-16 2007-06-21 Kosak Matthew K Shielded micelles for polynucleotide delivery

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAEDA ET AL.: "Preparation of poly(L-lactic acid)-polysiloxane-calcium carbonate hybrid membranes for guided bone regeneration.", BIOMATERIALS., vol. 27, no. 8, 2006, pages 1216 - 22, XP005193186, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/16143389> [retrieved on 20101020], DOI: doi:10.1016/j.biomaterials.2005.08.010 *
SCHIFFELERS ET AL.: "Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle.", NUCLEIC ACIDS RES., vol. 32, no. 19, 2004, pages E149, XP002397466, DOI: doi:10.1093/nar/gnh140 *

Also Published As

Publication number Publication date
WO2011011631A2 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
WO2011011631A3 (en) Nucleic acid delivery vehicles
WO2010008582A3 (en) Phagocytic cell delivery of rnai
WO2011008696A3 (en) Diagnostic methods and compositions for treatment of cancer
WO2010059253A3 (en) Methods and compositions for localized agent delivery
WO2011146518A3 (en) Pegylated c-peptide
WO2011053982A8 (en) Therapeutic nuclease compositions and methods
WO2009100137A3 (en) Magnetic cells for localizing delivery and tissue repair
EP4321177A3 (en) Carbohydrate conjugates as delivery agents for oligonucleotides
WO2009043353A3 (en) Micromirs
EA032867B9 (en) Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
WO2009143412A3 (en) Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
EP3257943A3 (en) Methods and vectors for cell immortalisation
EP2626427A3 (en) Sirna conjugate and preparation method thereof
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
WO2008137758A3 (en) Amino acid lipids and uses thereof
WO2011072246A3 (en) Tal effector-mediated dna modification
WO2012107908A3 (en) Nts-polyplex nanoparticles system for gene therapy of cancer
WO2011043913A3 (en) Novel cationic lipids with short lipid chains for oligonucleotide delivery
WO2010083170A3 (en) Cell stimulation using quantum dots
WO2009120919A3 (en) Fenofibrate dosage forms
EP2322121A4 (en) Stent for placement in living body, and stent delivery system
EP3252068A3 (en) Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
HK1166100A1 (en) Method for the cryopreservation of cells, artificial cell constructs or three-dimensional complex tissues assemblies
WO2011034906A3 (en) Recurrent gene fusions in prostate cancer
WO2012116073A3 (en) Amphiphilic dendron-coils, micelles thereof and uses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10802920

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10802920

Country of ref document: EP

Kind code of ref document: A2